The PRP market is valued at $828 billion, forecast to exceed $3 trillion by 2032.  Knee OA is one of the most common pathologies treated with PRP, either as a primary or adjunct therapy.

Platelet concentration, dosage, injection site, number of injections, and leukocyte count are among the treatment factors which should be correlated against standardized outcomes.  Informed patient consents, product(s) used, and adherence to Directions For Use are also key elements of establishing GCP datasets.  These are covered in this POC.

Each POC has a single Principal Investigator and a minimum of ten investigators.  They collaborate closely on the generation of a high-quality, validated and proprietary dataset with statistical and clinical significance.  That dataset, singly or in conjunction with other POC datasets, represent sustained value to product manufacturers, payers, researchers, and AI healthcare models.

Contributing physicians earn 85% of resulting POC license fees proportionate to their data contributions.  All POCs are based on RegenMed’s patented systems and processes, and do not interrupt clinical flow.  For more information on POCs, see here.